Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Biomoda Forms Partnership With Christiana Care
Biomoda has reported that the Helen F. Graham Cancer Center associated with Christiana Care Health System, will recruit a cohort of patients diagnosed with lung cancer to participate
Biomoda has reported that the Helen F. Graham Cancer Center associated with Christiana Care Health System, will recruit a cohort of patients diagnosed with lung cancer to participate
AdvanDx has received FDA 510(k) clearance for a 90 minutes protocol for its S. aureus PNA FISH and S. aureus/CNS PNA FISH tests. The protocol reduces the PNA
Genomic Health has reported that The Lancet Oncology has published positive results from a study of Oncotype DX in postmenopausal women with node-positive, estrogen receptor-positive breast cancer. The
Applied Biosystems, part of LifeTechnologies has entered into the flow cytometry instrumentation market with the Attune Acoustic Focusing Cytometer, a first cytometry system designed to use sound waves
Dynavax’s GMP manufacturing facility in Dusseldorf, Germany has been approved for the commercial production of hepatitis B surface antigen, a key component of Heplisav, an investigational adult hepatitis
Pharming has confirmed its interactions in a pre-BLA meeting with the FDA on a proposed marketing application (BLA or Biologics License Application) to obtain marketing approval for Rhucin
Clinuvel Pharmaceuticals had obtained positive results from an experimental trial evaluating the photoprotective effect of Afamelanotide in 16 patients. The objective of this pilot Phase II trial was
Celgene has presented data for three Phase II studies evaluating combination therapy with Revlimid (lenalidomide) and Rituximab in patients with indolent non-hodgkin’s lymphoma (NHL) during the 51st American
Sanofi-aventis has signed a strategic research alliance agreement with the California Institute of Technology (Caltech) in Pasadena, CA. The goal of the research collaboration, which will be known
Hemodynamic has completed its initial Phase 2 clinical study of its compound (HTI-101), a patented low-dose small-molecule investigational therapy intended for patients with treatment-resistant hypertension. The 12-week double-blind